<SEC-DOCUMENT>0001104659-22-120486.txt : 20221121
<SEC-HEADER>0001104659-22-120486.hdr.sgml : 20221121
<ACCEPTANCE-DATETIME>20221121070023
ACCESSION NUMBER:		0001104659-22-120486
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221117
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221121
DATE AS OF CHANGE:		20221121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		221403460

	BUSINESS ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105
		BUSINESS PHONE:		(781) 788-8869

	MAIL ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2230976d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20221117">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_KPRX_eyegatepharma.com_20221117 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20221117_20221117 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001372514 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityCentralIndexKey">0001372514</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="kprx-20221117.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-11-17to2022-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-17</xbrli:startDate>
        <xbrli:endDate>2022-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_905_edei--DocumentType_c20221117__20221117_zDOKXq2siH9a"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO SECTION&#160;13 OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b><span id="xdx_90B_edei--DocumentPeriodEndDate_c20221117__20221117_zKzfmJhwiSS"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 17, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--EntityRegistrantName_c20221117__20221117_zN3KNN6lIKH9" style="font-size: 14pt"><b><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityRegistrantName">KIORA
PHARMACEUTICALS, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20221117__20221117_zbS8WVDrUgR5"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><b><span id="xdx_90F_edei--EntityFileNumber_c20221117__20221117_zZIos2i7RnZ2"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityFileNumber">001-36672</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 49%; text-align: center"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20221117__20221117_zudofuIZhM8k"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityTaxIdentificationNumber">98-0443284</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20221117__20221117_z3LyqwIECpG3"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityAddressAddressLine1">1371 East 2100 South</ix:nonNumeric></span></b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine2_c20221117__20221117_z5C2120Atp88"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20221117__20221117_zNV472UqDm7c"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityAddressCityOrTown">Salt Lake City</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20221117__20221117_zE830vJeGtdk"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20221117__20221117_zTjXecJBGaR6"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b>&#160;</b></p>
</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 49%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20221117__20221117_zAFeldnqsMEk"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b></p></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90C_edei--CityAreaCode_c20221117__20221117_z3FRZupnbcU2"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20221117__20221117_zaMJItBSV0kb"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:LocalPhoneNumber">788-9043</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_902_edei--WrittenCommunications_c20221117__20221117_zv9R0YNU27E3"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Written communications pursuant to Rule&#160;425
under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90F_edei--SolicitingMaterial_c20221117__20221117_zIMX9EPmRmna"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12
under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20221117__20221117_zzABmE96fC06"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20221117__20221117_zhPheHpeHdV2"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class:</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 23%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 43%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--Security12bTitle_c20221117__20221117_zneeSUZC3lR6"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:Security12bTitle">Common Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--TradingSymbol_c20221117__20221117_zlAH0kN0B6eg"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" name="dei:TradingSymbol">KPRX</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_90C_edei--SecurityExchangeName_c20221117__20221117_ze4jJonCYHLa"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20221117__20221117_zfz6CKVaCzS7"><ix:nonNumeric contextRef="From2022-11-17to2022-11-17" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%">Item 1.01</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Entry into a Material Definitive Agreement</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously reported, on July 26, 2022, Kiora
Pharmaceuticals, Inc. (the &#8220;Company&#8221;) consummated a registered public offering, pursuant to which the Company <span style="background-color: white">issued
and sold (i)&#160;592,392 shares of its common stock, (ii)&#160;1,280 shares of Series E Convertible Preferred Stock, (iii)&#160;752,392
Class&#160;A Warrants (the &#8220;Class A Warrants&#8221;), and (iv)&#160;752,392 Class&#160;B Warrants (the &#8220;Class B Warrants&#8221;
and, together with the Class A Warrants, the &#8220;Prior Warrants&#8221;). Each of the Prior Warrants had an exercise price of $8.00
per share of underlying common stock, as adjusted to reflect the 1-for-40 reverse stock split consummated by the Company on September
27, 2022. The securities were offered by the Company pursuant to the Registration Statement on Form&#160;S-1 (File No.&#160;333-264641),
which was initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on May&#160;3, 2022, amended on July&#160;13,
2022, July&#160;19, 2022 and July&#160;21, 2022, and declared effective by the Commission on July&#160;21, 2022 (the &#8220;Registration
Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2022, the Company entered into
warrant exercise inducement offer letters (&#8220;Inducement Letters&#8221;) with holders of the Prior Warrants (collectively, the &#8220;Exercising
Holders&#8221;) pursuant to which the holders agreed to exercise for cash all of their Class A Warrants to purchase 654,609 shares of
the Company&#8217;s common stock in exchange for the Company&#8217;s agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;)
on substantially the same terms as the Existing Warrants, except as set forth herein, to purchase up to 654,609 shares of the Company&#8217;s
common stock. The Company expects to receive aggregate gross proceeds of approximately $3.12 million from the exercise of the Existing
Warrants by the Exercising Holders and the sale of the Inducement Warrants. The Company has engaged <span style="background-color: white">Ladenburg
Thalmann&#160;&amp; Co. Inc.</span> (&#8220;Ladenburg&#8221;) as its exclusive placement agent in connection with these transactions and
will pay Ladenburg a fee equal to 8% of its gross proceeds from the exercise of the Class A Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of the Prior Warrants to the public
and the issuance of the Common Stock upon exercise thereof have been registered on the Registration Statement. A prospectus supplement
relating to this reduction of the exercise price for the outstanding Class A Warrants was filed with the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also agreed to file a registration
statement covering the resale of the shares of the Company&#8217;s common stock issued or issuable upon the exercise of the Inducement
Warrants no later than 30 calendar days following the date of the Inducement Letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Each Inducement
Warrant is exercisable at a price per share of common stock of $5.97.&#160;&#160;Each Inducement Warrant will initially be exercisable
six months following its date of issuance, and will expire on the 18 month anniversary of their initial exercise date. The exercise prices
of the Inducement Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits,
stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. Subject to limited
exceptions, a holder of Inducement Warrants will not have the right to exercise any portion of its Inducement Warrants if the holder (together
with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates)
would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a holder prior to the issuance of any
Warrants, 9.99%) of the shares of common stock then outstanding. At the holder&#8217;s option, upon notice to the Company, the holder
may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding, with
any such increase becoming effective upon 61 days&#8217; prior notice to </span>the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summaries of the Inducement Warrants
and the form of Inducement Letters do not purport to be complete and are subject to, and qualified in their entirety by, such documents
attached as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K (this &#8220;Current Report&#8221;), which are incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Item 3.02</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Unregistered Sales of Equity Securities. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in Item 1.01 of this
Current Report on Form 8-K in relation to the Inducement Warrants and the shares of the Company&#8217;s common stock issuable upon the
exercise thereof is hereby incorporated by reference into this Item 3.02. The Inducement Warrants were issued in reliance upon an exemption
from registration pursuant to 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Item 3.03</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Material Modifications to Rights of Security Holders. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The disclosure set forth under Item 1.01 is incorporated
herein by reference into this Item 3.03 in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%">Item 8.01</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Other Events.</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 18, 2022, the Company issued a press release announcing
the signing of the Inducement Letters. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%">Item 9.01</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Financial Statements and Exhibits.</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-size: 8pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 19%"><span style="font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 79%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2230976d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">4.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2230976d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Inducement Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2230976d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2230976d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Inducement Letter</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2230976d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2230976d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Press Release of the Company, dated November 18, 2022</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td>
    <td><span style="font-size: 4pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 8pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>KIORA PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 52%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 30.25pt"><span style="font-size: 10pt">/s/ Brian M. Strem, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 30.25pt"><span style="font-size: 10pt">Brian M. Strem, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 30.25pt"><span style="font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">Date: November 21, 2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LboO/9ilQ0WcImOIt8VFKW7NSOt0j+Rb2m2IIRCSc74cIUZiSxtdIsNllaWQY1WXyiFkeENGc0XvSHb7GPzM8K6tY2Vcv/7AhDyDnpmNl8rfe2ejLRYxhPOJnE0iCaGMpws4HUTQ6QmZmy7QOK1KUKaAE1PNGp3idviQqzcZqto+6YxsNZkY5Dgc5A9EoYzgSI16ET8spGkiglFfgdgyPesu5mkdVbAusfJZdkD/HXwB4XRJHw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2230976d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 4.1</B></FONT></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&nbsp;BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>kiora
pharmaceuticals, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left">Warrant Shares: _______</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.875in; width: 50%; text-align: left">Issue Date: November&nbsp;__, 2022</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
 &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after May&nbsp;__, 2023 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00
p.m.&nbsp;(New York City time) on the 18-month anniversary of the Initial  Exercise Date (the &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from Kiora Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of
Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, New York 11598, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as
defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States
bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $5.97, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(A)&nbsp;= as applicable:
(i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is
(1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed
and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as
defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the
option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(X)&nbsp;= the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of
the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if
the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the resale
of the Warrant Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the
date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one
(1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery
of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying
(1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants,
9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged, subject to the limitation on fractional shares in Section&nbsp;2(d)(v). Any adjustment made pursuant to
this Section&nbsp;3(a)&nbsp;shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) other than a dividend or other distribution of the type described
in Section&nbsp;3(a)&nbsp;above (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such
case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is
taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to
be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder's right
to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a
result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder
until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (and all of its Subsidiaries,
taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or
indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or
any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares
of Common Stock or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction
(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by
paying to the Holder the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the
consummation of such Fundamental Transaction using the same type or form of consideration (and in the same proportion) that is being offered
and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in
the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among
alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of
Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will
be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction)
in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option
Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day
of consummation of the applicable contemplated Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable
Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of 100% and the 100 day volatility
obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the sum of the price per share being
offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, and (D)&nbsp;a
remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such
other consideration) within five Business Days of the Holder&rsquo;s election (or, if later, on the date of consummation of the Fundamental
Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
 &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with
the provisions of this Section&nbsp;3(d)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein. For the avoidance of doubt, except as expressly set forth in this Warrant, in no event does
this agreement result in the Company having an obligation to issue cash or other assets to the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all
or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash
or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Voluntary
Adjustment By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may, but in no event shall be
obligated to, at any time during the term of this Warrant, reduce the then current Exercise Price to any amount and for any period of
time deemed appropriate by the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to
the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered for resale, and the Holder
does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at 1371 East 2100 South, Suite&nbsp;200, Salt Lake City, UT 84105, Attention: Chief Executive Officer, email address:
bstrem@kiorapharma.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders.
Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such
Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective
on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set
forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time) on any date, (ii)&nbsp;the next Trading Day after the time of
transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;on a day that
is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to
whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder or the beneficial owner of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>kiora pharmaceuticals, inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">kiora
pharmaceuticals, inc.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 17%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 26%">&nbsp;</TD>
  <TD STYLE="width: 57%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 17%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 26%">&nbsp;</TD>
  <TD STYLE="width: 57%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 17%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 26%">&nbsp;</TD>
  <TD STYLE="width: 57%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 17%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 26%">&nbsp;</TD>
  <TD STYLE="width: 57%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 17%">Name of Investing Entity:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 83%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 3pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 35%">Signature of Authorized Signatory of Investing Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 65%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 3pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 3pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 3pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 96%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt"><FONT></FONT> <FONT></FONT></TD>
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt">(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address: </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 36%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm2230976d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2230976d1_ex10-1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25in; text-indent: 0.5in">November&nbsp;17, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[Name and address of warrant holder]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Re:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Reprice
and Reload Offer of Class&nbsp;A Common Stock Purchase Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To Whom It May&nbsp;Concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Kiora Pharmaceuticals,&nbsp;Inc.
(the &ldquo;<U>Company</U>&rdquo;) is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company
in consideration for the exercise of the Class&nbsp;A Common Stock purchase warrants set forth on your signature page&nbsp;attached hereto
(the &ldquo;<U>Existing Warrants</U>&rdquo;) currently held by you (the &ldquo;<U>Holder</U>&rdquo;). The shares of common stock, par
value $0.01 (&ldquo;<U>Common Stock</U>&rdquo;), underlying the Existing Warrants (&ldquo;<U>Existing Warrant Shares</U>&rdquo;) have
been registered pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-264641) (the &ldquo;<U>Registration Statement</U>&rdquo;).
The Registration Statement is currently effective and, upon exercise of the Existing Warrants, will, to the Company&rsquo;s knowledge,
be effective for the issuance of the Existing Warrant Shares. <B>Capitalized terms not otherwise defined herein shall have the meanings
set forth in the Existing Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for cash
exercising all of the Existing Warrants held by you on or before 9:00 a.m.&nbsp;(New York City time) on November&nbsp;18, 2022 (the &ldquo;<U>Warrant
Exercise</U>&rdquo;), the Company hereby offers you a reduction of the exercise price of the Existing Warrants to $4.77 per share and
the issuance of New Warrants (as defined and described below). As such, upon accepting this offer, Section&nbsp;2(b)&nbsp;of all Class&nbsp;A
Warrants issued pursuant to the Registration Statement is hereby amended and restated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;The exercise price per share of
Common Stock under this Warrant shall be $4.77, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company
hereby offers (i)&nbsp;to issue to you or your designees a new Common Stock Purchase Warrant (the &ldquo;<U>New Warrants</U>&rdquo;)
to purchase up to a number of shares of Common Stock equal to 100% of the number of Existing Warrant Shares issued pursuant to each
Warrant Exercise that occurs from and after the date hereof and prior to 9:00 a.m.&nbsp;on November, 2022, which New Warrant shall
be substantially in the form of <U>Annex B</U> hereto. The New Warrants will be exercisable six months following their issuance,
will expire on the eighteen (18) month anniversary of the initial exercise date. The original New Warrant certificates will be delivered
within two (2)&nbsp;Business Days following each Warrant Exercise pursuant to this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holder may accept this
offer by signing this letter below, with such acceptance constituting the Holder&rsquo;s exercise of the number of Existing Warrants as
set forth on the Holder's signature page&nbsp;attached hereto for an aggregate exercise price as set forth on the Holder&rsquo;s signature
page&nbsp;hereto (the &ldquo;<U>Aggregate Exercise Price</U>&rdquo;) on or before 9:00 a.m.&nbsp;(New York City time) on November&nbsp;18,
2022. Notwithstanding anything herein to the contrary, in the event the Warrant Exercise would otherwise cause the Holder to exceed the
beneficial ownership limitations (&ldquo;Beneficial Ownership Limitation&rdquo;) set forth in Section&nbsp;2(e)&nbsp;of the Existing Warrants,
the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number
of Warrant Shares permitted thereunder with the balance to be held in abeyance until notice from the Holder that the balance (or portion
thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the Existing Warrant which shall
be deemed prepaid thereafter, and exercised pursuant to a Notice of Exercise in the Existing Warrant (provided no additional exercise
price shall be payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the Company
agrees to the representations, warranties and covenants set forth on <U>Annex A</U> attached hereto. The Holder represents and warrants
that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited investor&rdquo;
as defined in Rule&nbsp;501 of the Securities Act, and agrees that the New Warrants will contain restrictive legends when issued, and
neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants (the &ldquo;<U>New Warrant Shares</U>&rdquo;)
will be registered under the Securities Act, except as provided in <U>Annex A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this offer is accepted
and this letter agreement is executed and delivered to the Company on or before 9:00 a.m.&nbsp;(New York City time) on November&nbsp;18,
2022, the Company shall (i)&nbsp;issue a press release disclosing the material terms of the transactions contemplated hereby (the &ldquo;<U>Press
Release</U>&rdquo;) (ii)&nbsp;file a prospectus supplement to the Registration Statement with the Securities and Exchange Commission disclosing
the reduced exercise price of the Existing Warrants and (iii)&nbsp;file a Current Report on Form&nbsp;8-K with the Securities and Exchange
Commission disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto
with the Commission within the time required by the Exchange Act. From and after the issuance of the Press Release, the Company represents
to the Holder that it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company or any
of its officers, directors, employees or agents in connection with the transactions contemplated hereby. In addition, effective upon the
issuance of the Press Release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and the
Holder or any of its Affiliates on the other hand, shall terminate. From and after the issuance of the Press Release, the Company represents
to the Holder that none of the Company&rsquo;s directors, officers, employees or agents will provide the Holder with any material, nonpublic
information that is not disclosed in the Press Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No later than November&nbsp;22,
2022, the closing of the shall occur at such location as the parties shall mutually agree. Unless otherwise directed by Ladenburg Thalmann&nbsp;&amp;
Co. Inc. (the &ldquo;Placement Agent&rdquo;), settlement of the Warrant exercise hereunder shall occur via &ldquo;Delivery Versus Payment&rdquo;
(&ldquo;DVP&rdquo;) (i.e., on the Closing Date, the Company shall issue the shares of Common Stock issued in the Warrant exercise in the
Holder&rsquo;s name and address and be released by the Transfer Agent directly to the account(s)&nbsp;of the Placement Agent as identified
by the Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically deliver such Warrant Shares to the
Holder; and payment of the aggregate exercise price therefor shall be made by the Placement Agent (or its clearing firm) on behalf of
the Holder by wire transfer to the Company). On or prior to the Closing Date, the Holder shall deliver or cause to be delivered to the
Company such Holder&rsquo;s aggregate exercise price for the Exercised Warrant Shares, which shall be made available for DVP settlement
with the Company or its designee. The date of the closing of the Warrant exercise shall be referred to as the &ldquo;Closing Date&rdquo;.
Except as set forth herein, the terms of the Existing Warrants, including but not limited to the obligations to deliver the Existing Warrant
Shares, shall remain in effect as if the acceptance of this offer was a formal exercise notice under the Existing Warrants. In addition,
upon the receipt of the shares of Common Stock pursuant to the Warrant exercise, the Holder agrees to instruct its prime broker to surrender
the Existing Warrants exercised hereunder to the Warrant Agent (as defined in the Existing Warrants) for cancellation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and
agrees that the obligations of the Holder under this letter agreement are several and not joint with the obligations of any other holder
of Common Stock purchase warrants of the Company (each, an &ldquo;<U>Other Holder</U>&rdquo;) under any other agreement related to the
exercise of such warrants (&ldquo;<U>Other Warrant Exercise Agreement</U>&rdquo;), and the Holder shall not be responsible in any way
for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement. Nothing contained in this
letter agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement
and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations
or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holder confirm
that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel
and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights
arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding
for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby represents
and warrants as of the date hereof and covenants and agrees from and after the date hereof until sixty (60) Trading Days after the date
hereof, that none of the terms offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification
or waiver thereof), is or will be more favorable to such Other Holder than those of the Holder and this letter agreement. If, and whenever
on or after the date hereof until sixty (60) Trading Days after the date hereof, the Company enters into an Other Warrant Exercise Agreement,
then the Company shall provide notice thereof to the Holder promptly following the occurrence thereof. The provisions of this paragraph
shall apply similarly and equally to each Other Warrant Exercise Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to
the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer agent fees,
stamp taxes and other taxes and duties levied in connection with the delivery of any Existing Warrant Shares. This letter agreement shall
be governed by the laws of the State of New York without regard to the principles of conflicts of law thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">***************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To accept this offer, Holder
must counter execute this letter agreement and return the fully executed letter agreement to the Company at e-mail: ___________, attention:
_________, on or before 9:00 am (New York City time) on ___________, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please do not hesitate to
call me if you have any questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely
    yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KIORA
    PHARMACEUTICALS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accepted and Agreed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%">Name of Holder:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 88%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; width: 30%">Signature of Authorized Signatory of Holder:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 70%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%">Existing Warrant Shares:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 83%">&nbsp;</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Existing Warrants being exercised contemporaneously
with signing this letter: _____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate Exercise Price of the Existing Warrants
being exercised contemporaneously with signing this letter: $___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrant Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial Ownership Limitation New Warrant: 4.99%/9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Delivery of New Warrant: _________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DTC Instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Existing Warrant Shares
shall be delivered to the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 20%">Broker Name:</TD>
    <TD STYLE="width: 3%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Broker DTC DWAC #:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Broker Contact:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Account #:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Annex A &ndash; Representations
and Warranties</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Representations, Warranties and Covenants of
the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement</U>. The Existing Warrant Shares are registered for issuance on a Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-264641)
(the &ldquo;<U>Registration Statement</U>&rdquo;) and the Company knows of no reason why such registration statement shall not remain
effective for the foreseeable future. The Company shall use commercially reasonable efforts to keep the Registration Statement effective
and available for use by the Holder until all Existing Warrant Shares underlying the Existing Warrants are sold by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company will have the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter
agreement by the Company and the consummation by the Company of the transactions contemplated hereby will be duly authorized by all necessary
action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection
therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of
the transactions contemplated hereby do not and will not: (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s certificate
of incorporation, bylaws or other organizational or charter documents; or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with
or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company
debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is
bound or affected, other than for which a waiver has been obtained by the Company; or (iii)&nbsp;subject to Section&nbsp;(d)&nbsp;below,
conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not have
or reasonably be expected to result in a material adverse effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Nasdaq
Corporate Governance</U>. The transactions contemplated under this letter agreement, comply with all rules&nbsp;of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Issuance
of the New Warrant</U>. The issuance of the New Warrants is duly authorized and, upon the execution of this letter agreement by the undersigned,
will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company, and the New Warrant
Shares, when issued in accordance with the terms of the New Warrant, will be validly issued, fully paid and nonassessable, free and clear
of all liens imposed by the Company. The Company has reserved from its duly authorized capital stock a number of shares of Common Stock
for issuance of the New Warrant Shares in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Legends
and Transfer Restrictions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
New Warrant and New Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any
transfer of New Warrant or New Warrant Shares other than pursuant to an effective registration statement or Rule&nbsp;144, to the Company
or to an Affiliate of the undersigned or in connection with a pledge, the Company may require the transferor thereof to provide to the
Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred New
Warrant and New Warrant Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be
bound by the terms of this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
undersigned agrees to the imprinting, so long as is required by this Section&nbsp;(i), of a legend on any of the New Warrant and New Warrant
Shares in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY&nbsp;BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">The Company acknowledges
and agrees that the undersigned may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer
or grant a security interest in some or all of the New Warrant to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule&nbsp;501(a)&nbsp;under the Securities Act and who agrees to be bound by the provisions of this letter agreement and,
if required under the terms of such arrangement, the undersigned may transfer pledged or secured New Warrant to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee,
secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate
undersigned&rsquo;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of New Warrant
may reasonably request in connection with a pledge or transfer of the New Warrant or New Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Certificates
evidencing the New Warrant Shares shall not contain any legend (including the legend set forth in Section&nbsp;(f)(ii)&nbsp;hereof), (i)&nbsp;while
a registration statement covering the resale of such security is effective under the Securities Act, (ii)&nbsp;following any sale of such
New Warrant Shares pursuant to Rule&nbsp;144, (iii)&nbsp;if such New Warrant Shares are eligible for sale under Rule&nbsp;144, or (iv)&nbsp;if
such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to its transfer agent (if required
by the transfer agent) and the undersigned (if requested by the undersigned) in connection with the removal of the legend hereunder. If
all or any portion of a New Warrant is exercised at a time when there is an effective registration statement to cover the resale of the
New Warrant Shares, or if such New Warrant Shares may be sold under Rule&nbsp;144 or if such legend is not otherwise required under applicable
requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then
such New Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required
under this Section&nbsp;(f), it will, no later than the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer
Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal
Date</U>&rdquo;), deliver or cause to be delivered to the undersigned a certificate representing such shares that is free from all restrictive
and other legends. The Company may not make any notation on its records or give instructions to the transfer agent that enlarge the restrictions
on transfer set forth in this Section&nbsp;(f). Certificates for New Warrant Shares subject to legend removal hereunder shall be transmitted
by the transfer agent to the undersigned by crediting the account of the undersigned&rsquo;s prime broker with the Depository Trust Company
System as directed by the undersigned. &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
a certificate representing Warrant Shares issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Public
Information Failure</U>. At any time during the period commencing from the six (6)&nbsp;month anniversary of the date hereof and ending
at such time that all of the New Warrant Shares may be sold without the requirement for the Company to be in compliance with Rule&nbsp;144(c)(1)&nbsp;and
otherwise without restriction or limitation pursuant to Rule&nbsp;144, if there is no effective registration statement covering the resale
of all of the New Warrant Shares and the Company (i)&nbsp;shall fail for any reason to satisfy the current public information requirement
under Rule&nbsp;144(c)&nbsp;or (ii)&nbsp;has ever been an issuer described in Rule&nbsp;144(i)(1)(i)&nbsp;or becomes an issuer in the
future, and the Company shall fail to satisfy any condition set forth in Rule&nbsp;144(i)(2)&nbsp;(a &ldquo;<U>Public Information Failure</U>&rdquo;)
then, in addition to the undersigned&rsquo;s other available remedies, the Company shall pay to the undersigned, in cash, as partial liquidated
damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the New Warrant Shares, an amount in
cash equal to two percent (2.0%) of the aggregate Exercise Price of the undersigned&rsquo;s New Warrant on the day of a Public Information
Failure and on every thirtieth (30th) day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a)&nbsp;the
date such Public Information Failure is cured and (b)&nbsp;such time that such public information is no longer required for the undersigned
to transfer the New Warrant Shares pursuant to Rule&nbsp;144. The payments to which the undersigned shall be entitled pursuant to this
Section&nbsp;(g)&nbsp;are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo; Public Information Failure Payments
shall be paid on the earlier of (i)&nbsp;the last day of the calendar month during which such Public Information Failure Payments are
incurred and (ii)&nbsp;the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments
is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure
Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit
the undersigned&rsquo;s right to pursue actual damages for the Public Information Failure, and the undersigned shall have the right to
pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive
relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
of Common Stock</U>. The Company shall apply to list or quote all of the New Warrant Shares on Nasdaq and promptly secure the listing
of all of the New Warrant Shares on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement</U>. As soon as practicable (and in any event within thirty (30) calendar days of the date of this letter agreement), the Company
shall file a registration statement on Form&nbsp;S-1 providing for the resale by the Holders of the New Warrant Shares issued and issuable
upon exercise of the New Warrants.&nbsp; The Company shall use commercially reasonable efforts to cause such registration to become effective
on or prior to the 30<SUP>th</SUP> calendar day after the initial filing date and to keep such registration statement effective at all
times until no Holder owns any New Warrants or New Warrant Shares issuable upon exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsequent
Equity Sales</U>. From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i)&nbsp;issue,
enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents
or (ii)&nbsp;file any registration statement or any amendment or supplement thereto, in each case other than the registration statement
registering the New Warrant Shares. Notwithstanding the foregoing, this Section&nbsp;(j)&nbsp;shall not apply in respect of an Exempt
Issuance. As used herein, &ldquo;Exempt Issuance&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options to employees,
officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee
members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose,
(b)&nbsp;securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this letter agreement, provided that
such securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (except for such decreases in exercise, exchange or conversion
price in accordance with the terms of such securities) or to extend the term of such securities, and (c)&nbsp;securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit
the filing of any registration statement in connection therewith until thirty (30) days after the Closing Date, and provided that any
such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Annex B &ndash; Form&nbsp;of New Warrant</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm2230976d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Kiora Pharmaceuticals
Enters Into Agreements to Raise $3.12 Million</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>From the Exercise of Previously Issued Class&nbsp;A Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Salt Lake City, Utah--(Newsfile Corp. - November&nbsp;18,
2022) - Kiora Pharmaceuticals,&nbsp;Inc. (NASDAQ: KPRX) (&quot;Kiora&quot; or the &quot;Company&quot;) announced today it has entered
into warrant inducement offer letters to raise $3.12 million in gross proceeds from the exercise of 654,609 Class&nbsp;A warrants issued
in the Company's public offering from July&nbsp;2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On November&nbsp;17, 2022, the Company reduced
the exercise price of all Class&nbsp;A warrants from $8.00 per share to $4.77 per share. On such date, Kiora also entered into warrant
inducement offer letters with certain investors pursuant to which the investors' immediately exercised 654,609 Class&nbsp;A Warrants at
the reduced exercise price of $4.77, and the Company issued to such investors new warrants to purchase 100% of the shares exercised pursuant
to the Class&nbsp;A Warrants. Such new warrants will, among other terms, become exercisable six months after issuance, have an exercise
price of $5.97 and a term of 18 months from their initial exercise date. The exercise of the Class&nbsp;A warrants is expected to result
in gross proceeds to the Company of $3.12 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Class&nbsp;A Warrants were registered
pursuant to a registration statement on Form&nbsp;S-1 and were issued pursuant to an Underwriting Agreement dated as of July&nbsp;22,
2022. The new warrants and the shares underlying the New Warrants are unregistered and are being issued in a private placement pursuant
to Section&nbsp;4(a)(2)&nbsp;of the Securities Act of 1933 (the &quot;Securities Act&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladenburg Thalmann&nbsp;&amp; Co. Inc. acted
as the exclusive warrant inducement agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Kiora Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Kiora Pharmaceuticals is a clinical-stage
biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for
the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited
and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis
(&quot;OPRA&quot;). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase
(&quot;DHODH&quot;) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T
cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated
with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a chemically cross-linked form of the natural
polymer hyaluronic acid, designed to accelerate corneal wound healing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition to news releases and SEC filings,
we expect to post information on our website,&nbsp;www.kiorapharma.com, and social media accounts that could be relevant to investors.
We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Some of the statements in this press release
are &quot;forward-looking&quot; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of
1995. These &quot;forward-looking&quot; statements include statements relating to, among other things, the development and commercialization
efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with
such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties
that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability
to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &quot;Risk
Factors&quot; contained in Kiora's Amendment No.&nbsp;1 to Annual Report on Form&nbsp;10-K/A filed with the SEC on July&nbsp;7, 2022 or
described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The
forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto
or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Investor Contact<BR>
Francina Agosti, Ph.D.<BR>
(617) 546-0742<BR>
<U>fagosti@reportablenews.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>kprx-20221117.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaaGSbOdzZR+KYkxtmBybem6rykuV/XrlCbu2fUG0coE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20221117" elementFormDefault="qualified" targetNamespace="http://eyegatepharma.com/20221117">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://eyegatepharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20221117_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20221117_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>kprx-20221117_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>kprx-20221117_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://eyegatepharma.com/role/Cover" xlink:href="kprx-20221117.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://eyegatepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2230976d1_ex10-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2230976d1_ex10-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X 70# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MI'=8T9W8*JC)8G  H 6LO6?$>C^'X1)JNHP6H/*J[?,WT4<G\!7E?C?XS+LG
MTWPSG=]UM0/;U\L?^S'\!T->-W5W<WUR]S=W$MQ.YRTDKEF;ZDT >U:M\>+:
M-WCTC2'F .%FN9-@/OM&3^HKE[KXV^*YV/DK86P[".$G_P!")KS>B@#O!\8?
M&8;/]H0D>GV9/\*T+3XX>)X#_I%OI]RO?=$RG\PV/TKS.B@#WS1/CEI-Y-'#
MJ]A-8%C@S(WFQCW/ ('T!KTO3M5T_5[;[1IU[!=P]-\,@8 ^AQT/M7QQ77?#
MW0_$6LZ]_P 2"\EL3" 9[M6*JBD]"!]XG!PO?% 'U)3)IHK>%YII$CB0%G=V
M 50.Y)Z4PR+:69DN9QMACW2S/A1@#ECV'K7SY\3/B3_PE#C2]):6/2HVR[GY
M3<-V)']T=@?J>U 'M7_";^%?^ABTS_P*3_&M73]3L=5M_M&GW<-U#G;YD+AE
MSZ9%?.'P^^'5YXONDNYP8='BDQ++WD(ZHG]3V^O%?2EK:P65K%:VL20P1*$C
MC08"@=@* ):**@GO+6U(%Q<PQ%N0)'"Y_.@">BHH+FWNE+6\\4H!P3&X;'Y5
M+0 4444 %%03WMI;,%N+J&)B,@22!21^-/EGA@B\V:5(X_[SL /S- $E%5X=
M0LKB01PW=O(YZ*D@)_(&K% !1110 44V21(D+R.J*.[' J.&[MKG/D7$4N.N
MQPW\J )J*** "BBH)[RUM6"W%S#$2,@22!<_G0!/15/^UM-_Z"%I_P!_E_QI
MR:E82MMCO;9V]%E4G^= %JBBB@ HHHH **** "BF3316\9DFE2-!U9V 'YFE
M1TD171E9&&0RG((H =1110 4444 %%%% ",RHI9F"J!DDG  KY^^)_Q)FUF\
MET?1;LKI2#;++$<?:6[\_P!SM[^XQ78_&;Q:=*T9-"M6Q<Z@I,S \I#G&/\
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M++Q-HL^EWZ$PRCAE^\C#HRGL17RUK&FWWA#Q3/9^:R75C,#',G&>A5A]1@T
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M;("*WB!>660@%SCYG8_A^ %>)?$SXF/XADDT?2'9-*1L22C@W)!_1/0=^IH
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M? ;_ ) &K?\ 7TO_ *#7J&I:=::OIT]A?0K-;3KM=&[C^A[YH ^??AA\0_\
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M-FQ9)[.X9 PX.5;@C\LU]6>&-<A\1^&['5(6!\^(>8!_"XX8?@0: ->BBB@
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MXE\-:?XIT>73[^)6R"8I<?-$^.&4_P"<T >:_";XBO=M!X9U9QYBILLYS_$
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ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139980923424464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 17,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1371 East 2100 South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-9043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm2230976d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20221117.xsd" xlink:type="simple"/>
    <context id="From2022-11-17to2022-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-11-17to2022-11-17">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-11-17to2022-11-17">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-11-17to2022-11-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-11-17to2022-11-17">2022-11-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-11-17to2022-11-17">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-11-17to2022-11-17">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-11-17to2022-11-17">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-11-17to2022-11-17">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-11-17to2022-11-17">1371 East 2100 South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-11-17to2022-11-17">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-11-17to2022-11-17">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-11-17to2022-11-17">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-17to2022-11-17">84105</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="From2022-11-17to2022-11-17">84105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-11-17to2022-11-17">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-11-17to2022-11-17">788-9043</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-11-17to2022-11-17">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-11-17to2022-11-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-11-17to2022-11-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-11-17to2022-11-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-11-17to2022-11-17">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-11-17to2022-11-17">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-11-17to2022-11-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-11-17to2022-11-17">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  LX=54'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  +.'55V=VW/>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R'9A,)/FTM%3!X,5-G8SMMJ:Q;&Q-9*^_1*O31G; ^QHZ?>G
M3Z#&1&5"PN<4(B9RF.]&W_59F;AF)Z*H +(YH=>YGA+]U#R$Y#5-SW2$J,V'
M/B)(SN_!(VFK2<,,K.)"9&UCC3()-85TP5NSX.-GZ@K,&L ./?:40=0"6#M/
MC.>Q:^ &F&&$R>?O MJ%6*I_8DL'V"4Y9K>DAF&HAU7)33L(>'O:O91U*]=G
MTKW!Z5=VBLX1U^PZ^76U>=QO62NYE)40E11[(17G2CR\SZX__&["/EAW</_8
M^"K8-O#K+MHO4$L#!!0    (  LX=5697)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M.:DGPR6AQ)2,6::)2QV'^##;KS'6:A:@J(GCK/.MK&7%)?U<0#5@D8(!5M,
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ "SAU5:K$(A8S 0  (@(   \
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M4$L! A0#%     @ "SAU5=G=MSWM    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "SAU59E<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  +.'553)W)&6,$   @$0  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "SAU59^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  +
M.'55EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  +.'55JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "SAU520>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "SAU5660>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2230976d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2230976d1_8k.htm">tm2230976d1_8k.htm</File>
    <File>kprx-20221117.xsd</File>
    <File>kprx-20221117_lab.xml</File>
    <File>kprx-20221117_pre.xml</File>
    <File>tm2230976d1_ex10-1.htm</File>
    <File>tm2230976d1_ex4-1.htm</File>
    <File>tm2230976d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2230976d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2230976d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20221117_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20221117_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20221117.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "KPRX",
   "nsuri": "http://eyegatepharma.com/20221117",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2230976d1_8k.htm",
      "contextRef": "From2022-11-17to2022-11-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2230976d1_8k.htm",
      "contextRef": "From2022-11-17to2022-11-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-22-120486-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-120486-xbrl.zip
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M*5C9@=C_@3<T1_GOQ+:)+&^-NI=IFN4?4$L#!!0    (  LX=57D?5#Y_PH
M &R'   5    :W!R>"TR,#(R,3$Q-U]L86(N>&ULS9U?4^NX&<;O.]/OH$UO
MVID30D*[,["'W>'DP ZS++"$<[;M3F='L47PX$BL[$#R[2O9EF-+>FU#IY*X
M@& ]K_S(^D62_TC^^,-VG:(7PK.$T=/1].!PA B-6)S0U>GHRV)\MIA?7HY0
MEF,:XY11<CJB;/3#]W_^$Q(_'[\9C]%%0M+X!'UFT?B2/K#OT#5>DQ/T(Z&$
MXYSQ[]!7G&[D%G:1I(2C.5L_IR0G(J'<\0GZQ\'TVR4:CP?D^Y70F/$O=Y=U
MOH]Y_IR=3":OKZ\'E+W@5\:?LH.(K8=EN,AQOLGJW ZWA]5/&?XQ3>C3B?RU
MQ!E!XGC1[&2;):<CN=]JMZ]'!XRO)K/#P^GDGS]?+:)'LL;CA,KC%I&1BI*Y
MV.*FQ\?'DR)520WE=LE3M8^CB;)3YRQ2DPY]PTF6G&2%O2L6X;RH]M[=(% A
M_QLKV5AN&D]GXZ/IP3:+1^K@%T>0LY3<D0=4%/,DWST+E+)$DC"JMCUR\F W
MDW(^D?$32E8X)['<T;'<T?1;N:._5)NO\)*D(R25@@^P7,>MO*J@B6NSMX0G
M+#ZG[W.M1WNR+[X[//\?"M",=UZ$>Y;C]%WFFY'.;5^3]QWQ?9S[(RW:>?*^
M(]V(_+_8SDW+;SZ\]N.:RHU7XE/+(MGFH@,CL3(IL^AH@8L]%!U#E7>=.XM:
M^::R-6?<++OL&8L\,Q(=K-C+)":)R'LV_>/O\N.X_%@47?S[^YR)T<#9,LLY
MCG*56U&4TY$E?:+;DLHSKKQA'O44L%),(B:ZI^=\G):'L@Q_X&QMW6U5<F9)
M_#U=UO'EH1&[ (RV9)QD;,,C\J:::;J%CE+E:)T*A1Q6$3K^LAA]7VC0;TKU
MGX^3?2Z.*EL,A39K0O-[D:NE%.UD5U5M,Z5JNID61$5;#.GUK"1(:CQ4\IG8
M>2P-7*1X92F"ENZJFJVV5#VW$H.H:)LCO:9K#9(BGU7]F6013Y[E\+ZK+"V9
M\XJWF#3JOZ$)"P/3&$Q#0^NQD;\CJT1V-=*&/.<E<F-'DP;H77<#G;;U?L$J
M#@*<(0[!GJ,9A.HHCRR=4;K!Z1UY9KP+H;;,-3DVDSHP34U0G%B,@7B46E2*
M/5+QRT:<S1.>[GK!,)2NV0"LZGAHLJ (L7L#(:GE_CFYYYAFB6S,>D$QI<Y/
M0P"SQBF)I@N*%< <?*I2Z_W3LG@D:2KO&6#:W[#8Q*Z)@0WKS)C*H*@![8'<
M%!&H"@D+G?,7.6H70Z>!!6[H?0)DV.YBJ!8'BY'N<"!)11B2<1YI:MRRZ.'(
M4+HF"+"JLZ/)@J+&[@WDI92C0A\&*.<T'H1)K?,#B6;3CD@E"A"0MK,^/(3:
M-QP721;AM/1S(;9E'46T:%U# MK503&$0<$"N0.!*0,4-T6(=VC^13 ?ADQ#
MZ0<8PZH=EUH6("RZMSY4I-X;*/,-YRWG<.\#2YW=S.TQ6]_7!71!P-)CSKC;
M6\I;L'CLC<YIGN0[^3S>]6:])-Q20%/BB@_(G.)"3P^"!\"4SD$I0U*'2J&W
MVE=W%6@N'X0$BZ3+W%)@-]DFH:T)B :K,8"(O;9X+M4;%7/12G&<7M*8;'\B
M.[!LALXM%X#--AB:*" R[,X -"HQ*M1(R+W!<<N3->:[11+U=!NFT"T>D-$V
M'[HJ($  :P AE1HM+N>^>Y5[O+V,!;#)0U(^7]Y#"JAW"TR/[38W@#@@?+H=
M A2)(-2.\@W3)8T8?V:-QR7F;",:P]V<Q?"(I2?*+5B#BM#&JS,D(,B&^ 10
M:X5^*)]I04S.#2HR0#(';]2=Q;$X6%GUYRJA9 H> ZO6+6$==MM<680!T02[
M QBJE!_4!R1CT T-"9S9&XH[\P_.;"@XLZ#!F;T'G/M7%A X1V\H[I%_<(Z&
M@G,4-#A'[P)'5+[W-F<N/M[P>_9J>^ ;5'K!QK1JA68O"P\9PUL?,#) CF]D
MB&]4BL'6#;_E["6A$3R,AN1>H %,6\G1M.'A8S?8QU ]2%9QOD&J!NN]7Q8E
M\]/:M$W:FYI2$QXH;6.]C4RI]HW%+<MRG/X[>>X\2;>+O2!B-6P%I:4,#Q>;
MO3YHRA@D@GR==%?8RAL@UNEJ6KJ[*<<66_LIQXW$($"P.3*G')=75TJ1CZJ6
MK'*"@9:AG>RLHBVFZGINI(51S:8AHY:+[[?0^/I"RY5ETMM'1N&'"TR)J]J&
MS*D:U].#J'7 E%[SA0P5.H]7[N4*%YF]*6^D.>OI=3MUQZX2@JAAW8W1;:MT
M#S7Z*T]RL?<Y6Z\WM+HS9'L&$="YJNE.FZK6K:(@".ARIM-0:5%;[ &-!4N3
M*,D3NOI9G)SR!-M*9A.Y@@(VJ(@P%4'@ -K26=@+D5)Z .&6$PDC$9513#B4
MBQSQFX<':^_?)78%1K]A!0BL# *47GLZ,")@'#4B4!F"BAC_Z%QFV8;P-P%D
M"?&$$6@>@,G0AX@49+(7K#+0-U\+$FU$?[F;SI;W29[:3CQ-B;/^"3!7]TY:
M>A!\ *9T'HHTQ![0=/;7Y=^0BO* P#6[YU@N:KO8K9<L!5;"LJI<@=!A4;%@
MD02! ^Q+)^*:H4J*2JVOE;):ABU%TM)=06"UI:J_E1A$Q=L<&8U J[X]-O_G
MV^A1&"/ 9 >[S'4W8#.I=P5-31 8=!@S3E8J*5):7Y,=]EW8JG]0L/(V*%CU
M# I6(0X*5D,'!2NO@P*UZW*9$M%&W2S39(6!11,[U:[!Z+"L,V*1!H4+[ ]L
M.^H0M(_QL=IFL>R:?)4 7Q<>+L0'2TD!G;/U-KMLU@MNVD1!<-+ES%ARLUP(
MKR%&4NV#C4V<Y"0N#5TD%-,HP6F]=*/MZGE_B#-B!IJOX>G1A\'1,),&4F68
M6F.Q#MPOP^GCLGOY$,>O)$U_HNR5+@C.&"5Q>;W%=G>I6^_VJ9L>V^T';P!Q
M$$@-<0@\?B.#QD\R"JFPZFJ9-YJ^LG1#<\R+.>S<UD(!.K?T #;;U&BB@&BQ
M.P,HJ<6H5/N;%%ZN7E$/O,IW)H&%A.2.IXAWFM9FBENU 7'3:1":-UZM.;(?
M+Y=1'J=SYD2^ZR)Y(9]QCBM_8)DAN>L)G%VF]9F;-FU &'4:!.=JUC%RN1JL
MN/*Z; V?B^'7BG4\?:ZIW"]>8U@TUZ^I)0$A8O/5L8H-1TKKC8?%&J?IITV6
M4)+!G9*F<LN#U6*;AY8D(!YLO@ >"BE26F\\G*\)7XGN[D?.7O/':@U9L'R
MVBT?G9;;G%BE ?'2Y0_@1H6@,D8M^^L/H.U^ ?1R!4BXM!:I8W1 LQHWABXD
M:"!S!C$IB>3UF&N6HWN&OF0$Y8\$G5>OU6NN7%_FX_,M*5$D)UR4HW4:8V[#
MJ$OL_(TIH&'CO2F&,@B8>NW![U"I(Y *\4#.C6"9-\_Q"B.7.5F#,RGZ0UQ1
M--2\8JE/'P11 TWJ7!5A[1/O(A#)2-^K*C47Y(>'?2V1X]&RQ: V6&XH@N $
MM 4-E9OO-_"WGM]FF2;11<HP?!6FI7&\BI]I3UO ;R\(B +3%;1L7R%$A=(;
M Y\P?>*;YSS:W7(6$2*?ULKJEJOO&MW :+?<O*E(;:(&A0;$VEO\ A3NLT"-
M/#XT>B_?%_SDP^ARA3D6/2T>L3B(-YL\DSVJ, =?,>\,<GPK8D !M!L2'1$!
MX3? )G1SHHA$1>@'5 :C1K3'\[9LOSHAB3_M[L@#X7).PSW9YI_$SIXZSCP&
MQ+H^JQM<'/TDKS<P"!#?ZA8Z!<Q0,P.TE,^955F@WV0FJ,C%]I[VYJ8K\4EL
M5IO$KR7.B-CR7U!+ P04    "  +.'55_,U5J%H'  #+6   %0   &MP<G@M
M,C R,C$Q,3=?<')E+GAM;,V<37/;-A"&[YWI?V#5LRQ+SD?MV,TXBI71Q(E=
MRTG:7C(0N9(P!@$5!"WIWQ<@144?!+B^9.V#+5,+8-]G09!+ #Q_NTQ%] @Z
MXTI>M+I'QZT(9*P2+J<7K2^C]N6H/QRVHLPPF3"A)%RTI&J]_?/77R+[<_Y;
MNQT-.(CD+'JOXO903M2;Z#-+X2SZ !(T,TJ_B;XRD;LC:L %Z*BOTKD  _:+
MLN&SZ.51]]4X:K<1]7X%F2C]Y6ZXJ7=FS#P[ZW06B\615(]LH?1#=A2K%%?A
MR#"39YO:CI?'ZY^R^+G@\N',_1JS#"++2V9GRXQ?M%R[ZV87)T=*3SN]X^-N
MY^]/UZ-X!BEK<^FXQ="J2KE:ZLIU3T]/.\6WE>F!Y7*L1=7&2:=R9U.S_98'
M[+<\R?A95KAWK6)FBK W-A-Y+=Q_[<JL[0ZUN[WV2?=HF26M"GY!4"L!=S")
MW%\;O4VKL((I,S"?,9TR%[6.L^CTE>V5UMVB[$S#Y*+U,-=+VT2OU^UV7[L&
M?M\Q,JNY[9T9=YVK%75V&I]KR$":0N^U/;!3!);&]BE(JHI<^T]RSW#C2JR[
M33=JNSZ6I[9!^[&T7'M3^2-4O.."<+%0>WJK?ET0SR ^FJK'3@+<DN]U_WOA
M/K;+CP4,^^_WHK'+<68TBTU5FV!C$$4;WZW-GDGG)WE6$;FWM=8[MFNQ[]=V
M!"]U'"F=@+;,J[J8CG?B=MA5UQ:=.=.VHG8\XV(3\HE6J8_0FH;R.+H-RS;Q
M\XA>6A\2Y\= L&D]TCT3)-,N!=1:-914WT,6:SYW;!K@[E@B&?=(&==H(T!=
MG4=W,.7.9^>.NQB#.Q@>(SQ%D/!/*$>-H%K"*%Q*F3-Q!W.E&^#O6B*9OZ!D
M7J>-$/5?.=,&M%AA:!\8(X&_I 3N44C(_%XSF7''" /]T!I)_17I#8E'(R'V
MT0R$< D?DZC>7F>/1/^:$KU?YS.!?_7HKOOV<H/GOU4$&8(_GDL(#M021N$6
M-%>)O=1K!/\#8R3Y4TKR'H7DS*]D@B6^,47G2/3 ]^01XA[P+&:B]&I@CV5A
MY#7F6.PDN6FC3'+T_P#3:/!;QECL).EJ@T0"Z/U<ZQV'@B.,WQJ+G211;1))
MP/U*&FY6;O;@<YZ.?SQXW>5]:(7E3)*<^D21\:V>3$CC)D9"C/<ML9Q)<M*0
M.#+6?:M),S&4"2P_PBH$^\ 42YLD%PW*(\-]JWG*]&K$X^8!Y- 6"YPD PT+
M)"-^SY;#Q"KC$UY.,S:#]Q;!\B=)/U%RR<(PE+'2<[7UN+FO<GMNKOHJ"0[Q
M#06Q(2')2Y\@G2PPETEBD67K/]=<0C<4CEIS]%P371 ",I\1^M[3T/?PZ$GR
MU4:9SPC]R=/0G^#1D^2LC3*IT??MQQM]KQ:>66VO,18[2<[:()$:>G'UN=&W
M6CWR<A56$_F#$EC\A*EL6"QU#-87?TROKRRQS G3VGIQU*QO56:8^)?/F^XR
MZ^VQW D3W)!0B@>39?S=0P[?<J4]$RQCDIRV5@X%5A=I#<S?C7<ML%!)$M4Z
M,01,KY6;0YDI&7R6>VB%94N2<?I$40S$;C5SYAT&MKY&KY8C&6;W91"@_*:Y
ML5[T59KF<OU<QS/#YC'%(B9)$X/R"'"/E. Q-UQ./]D[2,V9J&==9X<%39(4
M^H414+[5X"(.]M:\6#/FMC[HF\G$-Q*'[+'427+"9J'T](=9EH-^:@QJ2F$C
M09(>8D53C#D0YW887'5[XWNWB\<SXAQ887F3I(8^401\/ZM[S=QNPM$J'2OA
MWZI2:XBE3)((!J01@-[QI1[QG@D6+DD&6"N'<'RX6L8S)J?@7QE1;XF%3)(1
MAL21CL53U%@\?>)83)(9^D01\BW7I]NSZV8L^)3Y=[@%"Z#W_5!2#TBEV%M8
M;$-R>\]U6O@RL!_JT7M,L=!IMG"&Y%'@SA-N("G=&G#)9&Q3K\V>.T\FWUP*
M&P2:/9Y(T613!-] B(]2+>0(6*8D)&4Z$)HE\!;!1H)P3K)!+ED8OBJ16U*Z
M6("J/>>"QQ2+G7 NTB./;KUGN:AZ<STJ7SH2HNXK@85/."D9%DNX%LZ \YL_
MPGMFV-K+4 Q\); Q()R@#(LE7<.O^_9B-%7AN?@]0RQQPB6XM=+(0(]2)L2[
M/.,2LN XLV>(!4VXUK96&AGHJQ3TU YR'[1:F-EZ_VD(N*< %CSABMJ@5+H
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M,.'14V!HUST@,_.NM6MN)040CS]["IP#Q.5"PBHOH+04>-\Q9L3S9Q9[GQN
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MIB RJ-T"-<>,>H'+]J1^[D";$%CX*CT$0EL"7RC[TB$D$7BC9X\1&Y6%<<
M !L7:8M]N4)0WW$3KY].@WD<LZ F!CU@MC,V[8>&?9@N\^-F 0[?IZBP0%"I
MH0E]%.8AM(WO2M ?_N+_DG:^&UBL<$&'W!TE3>V8ND/3+OC.9(> G=XE\D'?
M\7UG+)_=F88_0D.N_)%+]>X[+HPK>N];5+\A&MAZS[%,8Y?(ER$D\5Z-WZ-W
M*'CF#_ ]\#2W]^>_U*JR*V8@_YN802DU!3Z_27H2@&P,9#+71+JBVD.N*"0
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M:'.DR8WF)0$<U'JY\BOR%R,1X@R(RR:.ZY.-\#NCX&68YQ-V"RWE:V9L[F!
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ME21YVSJ3'5\^\B"?BBKR8*0G^2.HTW&*CS]MN9+3AMN/0O* >;IK\FSIY\\
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MWN##5^/FH'3\^6Z_\KG[X?CN_7M!DO\'4$L#!!0    (  LX=569X#'81BD
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MYDVG# #S!"'#P+B/IWD# =UW^!LO:OHWJ2*.8P$] 8>!5QW=,CE$J' #88U
M?B3+CC^G%?9)*ZP)3U;!A,6X&7A ZTA$[J++'LI18<FA=ANA2<JDC=XEU+7H
M:_B#.0,\8 D3QUU4E5'X5M0[',/*6= U0,V+2F)A%V#;IKF(#H"*-]2!09S,
M8Q'7/VQNV?6!0)GG$4&F/RIY<1:8EHTNJ\0H0'64D"T-_(.<6K$Y!R,;'IB"
MBLM,M<?>A,1$R-J6QTK$#]9BF9 ZC2IWHS>NZI-H-9$:_)6BG0]-Z*VT1O$R
M2%"J :8",!TSC58BR_UEGS>Q=R>!RP;=*:S8HE6!>-)H"^!C<%2C>>G<0V**
MU-RDMZGY55UD+,R<$<ZJCD8Q"Q9/;BA,H<91,8K3PJKE,R#$''4Q]JT*CH&6
MF!1ZQ(H;(KT!#8&<1V+PU_#N&*?H=DYXCHJ>NQ;9]4S0P8W+28L,U+DY.LNR
M+&;H7>W1<NI1@*,(X\%G,/J3<P+!#/:+;_D-LA)(3D(SOK9O$,>%1==6O<L>
M<U@@*E15]_U/C_^U<H7LBEI:(CG]_LP9$-FB'C^*Y^.Z8>:14N,J8.N<K5#:
M (Y;;; H:R_CU(!V +<_YA&B+QPW0TI@#<QA0[U==FC4O?J$%$IPHHJI7HR0
M\Z:NPT9EZ,?/YL,X&H'N+F!#^@J@U@-VFCSFAP >Z.I@]%DB0)E"]N/($4W#
M!6GJ$<7=P#@!JZ0'T^6 IBG^BJ!/%R@<\.ESDG\<D$O8,/'GOXIT-E3%F^:#
M(\3LR92Z 2!!/[/!EF))AM$#"4,+5C)!71U=+,A94@SUS:)8@P$$D#L7(XVE
M ;UH<0B=.E-#@NPR1\.%V%>:(^2'IKQ$S\XR/-55X&0(UL#:AR?!"D%OCEC@
M:0(J!(6EF.L":.0(JW,TO$G+Y7<9DY"THH0\2E\4=1-<=#5VZUP( 00\6)I0
MB\2T"-UP!D(R7$0%]QGU,4+L<9_)B&-EGFR$O"N[^WM([,-4(9'1(=2E)8C)
M4%I:SBN')+X!=-.",B.V;SIB,.J"GLET3@R=GYW-RSDY5XE$-M2')*:L&Q^2
MI'-FSGF@89W#>7X.6K2.8<?BP_A>S[)M% K(#T8;%8%Z#&87L^\^XH./AX'6
M7HJ\E-5;9<\)-^]2"#=V$6D[^!YSQ87Z!= /9/"Q7LS\)-V.==/L_7(<R/ -
ML]&SQ+4K -P#@#<I(.+YOUJ_]=BXM(4H"6G=44]23W/"WTF7E?P+X>MGR(!1
M;R/@R6'$"RL$0)5+YTFY5E1=2#68X\DSNYQ$J/;)V+RD;>;5E,R1T5$0UE05
M[U[CL PA(.U91M'W&-:6IPFFGJ" X[-I&DZ6;Z&RS2$#/CN+#*WN39+[Z -U
M[HX9H*4%6'V-Z#5"MCH"N.9XT),HGY$6.C3P_H0":U5Y>HGN_M("OJKOKF^H
M(Q(9+L#1C$0R&B_10H+BUN1P2RON?0<.AWH(LAK&M,+#YB$,G*.I?G:!Q\J!
M2U]HD)=HE^'[0!\!/595*BL'$8HVY,5F--N]DR9&M$0';G8X.Y/+IH4C"9&&
M4!1JW<!@NC7<O)G/CF"&=$7-;$CN\$KE<%Z2""%GH%>D0HT!/K*'U31<MV-!
MRMO)S0P-:/B?-1\BM(FE3!L]2"L&V"5JL13#"L-#X@3U]NMR0D=%U>IVK(85
M4NX5;*H>;:\?4 5MO2,F2L" F8]*.GW -^!:PSS]Q'11D!DQ1L]PL_7A?9^>
MD]?F%RJM.CD:1UN7Q \ :1S3>=UC:7\]]^;3;764$>:]PG$E+K"M?L%<,/CZ
M;KR?=Y -?8OIZ@$X+2"WU=DB@R?ZN1Y&HVV%.<0,;-"D (1/*YY4^Q9^$Z2S
M/CA[OU TMLVZ\_Y>ZZ(,.;%P,V%(0;++LE< I'5A@&4#/T4] EG\QS0*'2VU
M@4F@L5%%PY.Y?*,,5K6&CM_0@_OZPYLC&G(Y^3.P0WE6OW90]W09* "A>Y24
M #?_6GV>I1AGWXY:33L3:[.JD2",2!87&:;6H1J @3E8X:5>=#M6I<A,3H(J
M,"8;0!GN&Q4%OUW:PJKE4L"7XKOBD+8R $/V]=/NR1$K=DJH4G\"B[VBT'I1
MQPZBGM<])%0'T'81_8I):F$5[H@C]IK,)@GPTKGKHDA'D6;'AQ:,PP@T!N_3
M\+@_11@KF"A4P,M%C]1 8"JE=6?.9YDW<U>M!I:2AX=%@ #8L0,'TTAH<M0Q
MSO-TGC$1X$%+)AB=2>44\Q6N'H)N ^59_W$+B5]K.T2]B(U_=1M PW]V'_:T
M5B-JA9U5Z8I<4OF,8T?A%U/4"8$B,D.L$0PC,L!'4:9+K^TDYAPT0!VF?ZYT
M6SOVIL<7X@0F)]4EPG">%";F$\*OBS0O*K$O'_5&K(R9*FKKS-.2E%J,8J,[
M!N; ">CF6JA9<]9,.B^#.#OKD_PHXBQGZ>(S5AUN)FWG+146E8!V6U!FU:1R
M3#Y? 1Y"XN-<4)V$ 7*$],(2"VP'$QO(E4[F(V(0\(HL_;OXC4+T%!P)'7QA
MC+,EN%F-JP8NV!4I?YS)442? =QK/VZNH]]BS+;<HJB]PWF6Z:2W[&.TMMS$
M6L5+YUUG ]>A6_(!$,EB C&CVBP=<[H=99.D:)99JX_R2GKH;\2/)<8XP_#6
M1%^D.=G,E@%5<1&]=4 '/KI9X7Q-*7=J?\)HC_%6U&%@+>1>^.M@5A[*'BM(
M9T=^1*!;"3G./*IZQ)W3A_RY8K<*V&JQ"><9JJ18LA<O)Q5<WF/.1&,67OO#
MVT@Z!V#I;-KM\+PZR^*%=?;'S(4I]Y5]8A2.7\G'_Q;$/L"M,H.3(]&L!4V
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M[_=7"6Q39ELJ;+5>:L+LD1704NW ^L?OR_]]=3!;K@U2PX*O<E<KJHF%U5+
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MK<)5DG:5B6&S4E&,$/C<)%2*!N%>TA3!'4VBEBR+P7K%;X8Z^93/LW)$32R
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M"H+X7ZD*-MA$+MVH'2[U>[Q.EV#F.H$S=HUFY5XO]OJDP#8S,NY="<R'4 3
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M6*KE<^MVY.#XRB%=%<HI'H[.=\")M6>;>/\%AU@# ^5Q3OG@2#S,!5&[PFK
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M$N!9M._D$E:)L]SY!+1E ;8#__Z?!>R/X K&-$/E3/L3KLE2\-\R-"=&.CS
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M0@N*/],-%_R,=P[6=/7"0FKH8%\O6I\A>Y/UI2^1-OFVI4V$LHF*<E"M*@X
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M*8"/YO)86U;SNHJM_W_$8"0H9Y>5[SSVB]GX"F*[HHWO;Q7?PI>A=1GZ"_(
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M%NV9K%YN4-\ DR-"G10QZQE&A--:OBC@,!Y'E-6O*M!2)@Q2EI301QES%:_
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MKGZT>Z0J/N\_.(HPV"U(XN16OHOR2ZP[,SPS:,W$%L^2X/2FL]HF*&<3Q6I
MI"(CJFF7@2B+^>0L!GGY@DBZ1C.PP&'W*,@(-=%M2H<<<4FJRT(6XAJTX,O:
MM(M/L5)+YT/,\@X5CU4Z4;%+17\SI5:D$5/GNS76OO U3S?).[3B>]U/QL>
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M"]"37XN$Q-WD3B)TV"C.3-A%8N)&);:F(SM!IY IJI=*K2F&<X0=--3MK\S
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M              "  <2F  !T;3(R,S Y-S9D,5]E>#DY+3$N:'1M4$L%!@
0   '  < T $  $FQ      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
